Quantitative Analysis of Cell Free Plasma DNA as A Prognostic Biomarker in Acute Ischemic Stroke Patients

Abstract

Stroke has become a major cause of mortality and disability worldwide, newlineand Despite advances in screening programmes, drugs, and monitoring newlinetechnologies, more practical biochemical tests are still needed to follow newlinetreatment response and support clinical decision-making. newlinePatients who have suffered a stroke may release cell-free DNA from newlineinjured neurons, which could be a useful indicator of how well the patient newlinewill recover. The level of a highly sensitive blood biomarker on acute newlineischemic stroke and cell-free plasma DNA were investigated in this newlinestudy. newlineThe study comprised 188 patients who had experienced an acute ischemic newlinestroke. Cell-free DNA was extracted from 1 ml of plasma using a newlineQIAamp Circulating Nucleic Acid Kit (Qiagen, Germany). The amount newlineof DNA extracted was assessed using a Nanodrop spectrophotometer newline(Thermo Scientific). The plasma Cell- free DNA level was estimated with newlinea real-time PCR assay for the and#946;-globin gene (Qiagen- Rotor- Gene Q newlineMDX, Germany). newlineThe clinical assessment was performed with the National Institutes of newlineHealth Stroke Scale (NIHSS) at the time of admission. After a period of newlinethree months from the onset of stroke, the modified Rankin scale mRS newlinescores was estimated. newlinePatients with higher NIHSS at admission and mRS 3-month scores had newlinehigher levels of cell-free DNA (plt0.05). Compared to other stroke risk newlinefactors, the markers were shown by the regression analysis to be linked newlinewith the mRS result (R2=0.224). A level of cell-free DNA 10000 kilo newlinegenome equivalents/L was consistent with favourable stroke outcomes newline(plt0.05). newlineA prospective therapeutic use for a low-cost, simple blood-based test and newlinecell-free DNA is suggested by whole cell-free DNA measurement, a less newlinecomplex and less expensive biomarker. This can help in clinical newlineevaluation and providing the best care for patients who have had ischemic newlinestrokes. This biomarker could be used to predict the long-term outcome newlineof a stroke. newline